References
1. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;148(12):2561-8.
2. Lortholary O, Lefort A, Tod M, Chomat AM, Darras-Joly C, Cordonnier C. Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. Lancet Infect Dis 2008;8(10):612-20.
3. Sime FB, Roberts MS, Warner MS, et al. Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancy. Antimicrob Agents Chemother 2014;58(6):3533-7.
4. Naeem D, Alshamrani MA, Aseeri MA, Khan MA. Prescribing Empiric Antibiotics for Febrile Neutropenia: Compliance with Institutional Febrile Neutropenia Guidelines. Pharmacy (Basel) 2018;6(3).
5. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. CID. 2016;62(10):e51-77.
6. Rosa RG, Goldani LZ, dos Santos RP. Association between adherence to an antimicrobial stewardship program and mortality among hospitalised cancer patients with febrile neutropaenia: a prospective cohort study. BMC Infect Dis 2014;14:286.
7. Paskovaty A, Pflomm JM, Myke N, Seo SK. A multidisciplinary approach to antimicrobial stewardship: evolution into the 21st century. Int J Antimicrob Agents 2005;25(1):1-10.
8. Cheng VC, To KK, Li IW, et al. Antimicrobial stewardship program directed at broad-spectrum intravenous antibiotics prescription in a tertiary hospital. Eur J Clin Microbiol Infect Dis 2009;28(12):1447-56.
9. Yeo CL, Chan DS, Earnest A, et al. Prospective audit and feedback on antibiotic prescription in an adult hematology-oncology unit in Singapore. Eur J Clin Microbiol Infect Dis 2012;31(4):583-90.
10. So M, Mamdani MM, Morris AM, et al. Effect of an antimicrobial stewardship programme on antimicrobial utilisation and costs in patients with leukaemia: a retrospective controlled study. Clin Microbiol Infect 2018;24(8):882-8.
11. Ruiz-Ramos J, Frasquet J, Poveda-Andrés JL, et al. Impact of an antimicrobial stewardship program on critical haematological patients. Farm Hosp 2017;41(4):479-87.
12. Storey DF, Pate PG, Nguyen AT, Chang F. Implementation of an antimicrobial stewardship program on the medical-surgical service of a 100-bed community hospital. Antimicrob Resist Infect Control 2012;1(1):32.
13. Rattanaumpawan P, Thamlikitkul V, Upapan P. 239A Cluster-Randomized Controlled Trial of Trained Pharmacists and Infectious Disease Clinical Fellows for Approval of Restricted Antibiotics in Hospitalized Medical Patients at Siriraj Hospital. Open Forum Infect Dis 2014;1(suppl_1):S103-S.
14. Apisarnthanarak A, Lapcharoen P, Vanichkul P, Srisaeng-Ngoen T, Mundy LM. Design and analysis of a pharmacist-enhanced antimicrobial stewardship program in Thailand. Am J Infect Control 2015;43(9):956-9.
15. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections Version 2.2020 June 5, 2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf. Accessed Dec 27, 2020.
16. Madran B, Keske S, Tokca G, et al. Implementation of an antimicrobial stewardship program for patients with febrile neutropenia. Am J Infect Control 2018;46(4):420-4.
17. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31 Suppl 4:S131-8.
18. Kollef MH. Rebuttal From Dr Kollef. Chest 2017;151(4):744-5.
19. Kollef MH. The importance of appropriate initial antibiotic therapy for hospital-acquired infections. Am J Med 2003;115(7):582-4.
20. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52(4):427-31.
21. Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 2016;27(suppl 5):v111-v8.
22. van den Bosch CM, Geerlings SE, Natsch S, Prins JM, Hulscher ME. Quality indicators to measure appropriate antibiotic use in hospitalized adults. Clin Infect Dis 2015;60(2):281-91.
23. DeWitt KM, Weiss SJ, Rankin S, Ernst A, Sarangarm P. Impact of an emergency medicine pharmacist on antibiotic dosing adjustment. Am J Emerg Med 2016;34(6):980-4.
24. Ohashi K, Matsuoka T, Shinoda Y, et al. Clinical outcome of pharmacist-led prospective audit with intervention and feedback after expansion from patients using specific antibiotics to those using whole injectable antibiotics. Eur J Clin Microbiol Infect Dis 2019;38(3):593-600.
25. Harris PNA, Tambyah PA, Lye DC, et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E. coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA 2018;320(10):984-94.
26. Chotiprasitsakul D, Srichatrapimuk S, Kirdlarp S, Pyden AD, Santanirand P. Epidemiology of carbapenem-resistant Enterobacteriaceae: a 5-year experience at a tertiary care hospital. Infect Drug Resist 2019;12:461-8.
27. Righi E, Peri AM, Harris PN, et al. Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. J Antimicrob Chemother 2017;72(3):668-77.
28. Ko JH, Kim SH, Kang CI, et al. Evaluation of a Carbapenem-Saving Strategy Using Empirical Combination Regimen of Piperacillin-Tazobactam and Amikacin in Hemato-Oncology Patients. J Korean Med Sci 2019;34(2):e17.
29. Kirk A, Pierce J, Doll M, et al. Effect of carbapenem restriction on prescribing trends for immunocompromised wards at an academic medical center. Am J Infect Control 2019;47(8):1035-7.
30. Snyder M, Pasikhova Y, Baluch A. Early Antimicrobial De-escalation and Stewardship in Adult Hematopoietic Stem Cell Transplantation Recipients: Retrospective Review. Open Forum Infect Dis 2017;4(4):ofx226.
31. Paskovaty A, Pastores SM, Gedrimaite Z, Kostelecky N, Riedel ER, Seo SK. Antimicrobial de-escalation in septic cancer patients: is it safe to back down? Intensive Care Med 2015;41(11):2022-3.
32. Livorsi DJ, Nair R, Lund BC, et al. Antibiotic stewardship implementation and patient-level antibiotic use at hospitals with and without on-site Infectious Disease specialists. Clin Infect Dis . 2020; ciaa388.
33. Keng MK, Sekeres MA. Febrile neutropenia in hematologic malignancies. Curr Hematol Malig Rep . 2013 Dec;8(4):370-8.
Table 1 Baseline characteristics